tbuckley/cabot-search huggingface dataset:
Abstract 1954: Circulating microRNA-21 predicts the response to hypomethylating agents in patients with myelodysplastic syndromes.
Authors: Yoo Hong Min, Jae Yong Cho, Yundeok Kim, Yeo-Kyeoung Kim, Soo Jeong Kim, Jin Seok Kim, June-Won Cheong, Hyeuong Joon Kim
Journal: Cancer Research (2013)

Abstract Background: Although hypomethylating agents therapy have considerably improved the outcomes of patients with myelodysplastic syndromes (MDS), the discovery of sensitive non-invasive biomarkers that can facilitate the prediction of response to hypomethylating agents (HMA) and therapeutic outcomes are highly desirable to determine optimized strategies of epigenetic therapy for MDS. Circulating microRNAs have been evaluated as potential biomarkers for cancer diagnosis and prognosis prediction. Purpose: We evaluated the significance of miR-21 expression in serum as a biomarker for predicting response in MDS patients treated with HMA. Patients and methods: Serum miR-21 level was measured by quantitative real-time PCR in 58 MDS patients at diagnosis and 14 healthy controls. We analyzed the correlation between serum miR-21 level and clinical characteristics and response to HMA and survival. Results: We found that serum miR-21 level was significantly downregulated in patients with MDS than those in healthy controls (P&amp;lt;0.001). Moreover, miR-21 level was significantly lower in patients with response (CR, mCR, PR and SD with HI) to HMA compared to those without response (median, 0.9414±0.6349 vs. 1.1443±0.7707; P=0.041). Receiver-operator characteristic curve analysis indicated that serum miR-21 was useful in differentiating responder from non-responder with AUC of 0.648. At a cut-off value of 1.2613 for serum miR-21 level, the optimal sensitivity and specificity were 83.3% (95% CI: 68.6-93.3%) and 45.8% (95%CI: 25.5-67.1%), respectively. Patients, whose miR-21 level at diagnosis was higher than cutoff level, were defined as high miR-21 group (n=17) and the low miR-21 group representing the remaining 41 patients. We found that patients in high miR-21 grooup, compared with those in low miR-21 group, had a shorter median PFS (P=0.001). On multivariate analysis, Serum miR-21 level remained as a significant prognostic factor for response to HMA and PFS. Conclusion: In this study, we evaluated the levels of serum miR-21 in patients with MDS, and found that serum miR-21 level predicts response to HMA and PFS in MDS. Although this prognostic significance should be validated in an independent set of patients receiving HMA, serum miR-21 level is a promising biochemical marker for response prediction to HMT. Citation Format: Yoo Hong Min, Jae Yong Cho, Yundeok Kim, Yeo-Kyeoung Kim, Soo Jeong Kim, Jin Seok Kim, June-Won Cheong, Hyeuong Joon Kim. Circulating microRNA-21 predicts the response to hypomethylating agents in patients with myelodysplastic syndromes. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1954. doi:10.1158/1538-7445.AM2013-1954
Abstract 1290: The ability of the transcription factor p63 to induce selected gene expression modules associated with mesenchymal to epithelial transition of prostate cells
Authors: Jan Roger Olsen, Xi-Song Ke, Kari Rostad, Margrete R. Hellem, Yi Qu, Biaoyang Lin, James B. Lorens, David R. Micklem, Hallvard Haugen, Karsten Gravdal, Ole Johan Halvorsen, Lars A. Akslen, Varda Rotter, Anne Margrete Oyan, Karl H. Kalland
Journal: Cancer Research (2012)

Abstract Genome-wide gene expression analysis identified p63 as one of the most consistently under-expressed transcription factors in prostate cancer samples compared to matched benign prostate tissue. Two alternative p63 promoters generate two different N-terminal variants, TA or ΔN which contains and lacks the transactivating domain, respectively. Differential splicing generates multiple additional isoforms. The activity and interactions of the different isoforms remain unresolved. Isoform-specific real-time quantitative PCR assays revealed that ΔNp63α is the predominant isoform in epithelial prostate tissues, but other isoforms are detectable. Our group has established an experimental cell culture model based upon primary, immortalized prostate epithelial cells (EP156T cells), where p63 was shut down when EP156T cells underwent epithelial-to-mesenchymal transition (EMT) to become EPT1 cells. Subsequently, several additional mesenchymal like cell subtypes with additional malignant features, including anchorage independent growth in soft agar and ability to grow at much higher density in monolayers, were derived from EPT1 cells. All of these subtypes exhibited very low p63 expression. To examine the potential of p63 to induce mesenchymal to epithelial transition (MET) in this EMT model, we have stably re-expressed the ΔNp63α and TAp63α isoforms in different mesenchymal like cells of the model using retroviral/lentiviral vector transductions. Genome-wide gene expression analyses and phenotypic cellular assays revealed that the ΔNp63α isoform induced re-expression of multiple genes involved in cell adhesion. But this was not associated with complete MET induction. Cells re-expressing ΔNp63α obtained an intermediate morphology with both epithelial and mesenchymal traits, and with actin filaments organized in stress fibers. ΔNp63α re-expression significantly compromised migratory but not invasive ability of the cells. Based upon these findings we want to investigate whether p63 may compromise epithelial to mesenchymal plasticity in an animal model of tumorigenic cells and if there is differential effect on primary tumor growth compared to metastatic growth. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 1290. doi:1538-7445.AM2012-1290
Nicotine Medications for Smoking Cessation
Authors: J E Henningfield
Journal: New England Journal of Medicine (1995)

Cigarettes are among the most addicting products known, and the vast majority of people who quit smoking relapse within days.1,2 In the United States, less than 10 percent of the nearly 20 million people who quit smoking for a day remain abstinent one year later.3 Thus, only 2 to 3 percent of smokers become nonsmokers each year.3 Medications that contain nicotine enable health care providers to increase markedly the ability of their patients to achieve and sustain tobacco abstinence. This review summarizes the scientific rationale for nicotine medications, to help clinicians optimize their use.Pathophysiology of Nicotine AddictionClinical . . .
Pleural Activity in a Patient With a Lumbopleural Shunt After Intrathecal Injection of Tc-99m DTPA
Authors: BARRY E. CHATTERTON
Journal: Clinical Nuclear Medicine (2000)

A 32-year-old woman with a 6-year history of benign intracranial hypertension was referred with headache symptoms for assessment of patency of a lumbopleural shunt. This had been inserted after failure of several previous lumboperitoneal shunts. Chest radiographs showed the shunt catheter to be in situ, but there was no evidence of pleural effusion. After intrathecal administration of Tc-99m DTPA, activity was seen in the right pleural space, confirming shunt patency.
TV: Diamond is forever
Authors: J. Aronson
Journal: BMJ (2001)

A Lump in my Throat , BBC 2, Sunday 15 July at 9 pm

The John Diamond cancer industry rolls on, with a little of what Diamond himself called “a squalid and self-referential cynicism.” First the newspaper column; then the book C. Because Cowards Get Cancer Too , the television documentary, and the stage play; and last month, posthumously, another book (about alternative medicine) and a television dramatisation.

When Diamond, already an award winning journalist and broadcaster, first discovered a lump in his throat in March 1997, he wrote about it in the Times , …
Training infection control and hospital hygiene professionals in Europe, 2010: agreed core competencies among 33 European countries
Authors: S Brusaferro, B Cookson, S Kalenic, T Cooper, J Fabry, R Gallagher, P Hartemann, K Mannerquist, W Popp, G Privitera, C Ruef, P Viale, F Coiz, E Fabbro, C Suetens, C Varela Santos
Journal: Eurosurveillance (2014)

Binary file ES_Abstracts_Final_ECDC.txt matches
RESECCIÓN ENDOSCÓPICA Y QUIRÚRGICA DE PÓLIPOS GRANDES
Authors: P Iruzubieta Coz, D Hernandez, Á Terán Lantarón, J Cabezas Delgado, MT Arias Loste, B Castro Senosiain, M Rivero, L Martin Ramos, S Menéndez, J Crespo García, J De La Peña García
Journal: Endoscopy (2013)

Introducción: Clásicamente se ha considerado el tamaño límite de resección endoscópica (RE) de pólipos en 3 cm dado la posibilidad de complicaciones graves. Cada vez con más frecuencia se están resecando pólipos de gran tamaño endoscópicamente, y hasta ahora no se han analizado las diferencias con los resultados quirúrgicos. Objetivo: Comparar los resultados de una serie de pacientes con pólipos de ≥3 cm en los que la primera opción fue la RE frente a la resección quirúrgica (RQ). Material y Método: Búsqueda retrospectiva de resección de pólipos, tanto vía endoscópica (n = 108) como quirúrgica (n = 30), de ≥3 cm desde abril 2010 a abril 2013, analizando las características de los pacientes, pólipos, complicaciones, estancia media hospitalaria y éxito de resección entre ambas cohortes. Resultados: Las técnicas endoscópicas fueron: polipectomía en 82 casos (76%), mucosectomía en 18 (16,7%) y DES en 5 (4,6%). En la tabla se muestra las características de nuestros pacientes y los pólipos resecados. Ambas cohortes no difieren en edad ni comorbilidad. Los pólipos resecados quirúrgicamente fueron de mayor tamaño y de predominio planos/sésiles, pero no hubo diferencias en cuanto a la localización o histología. Tanto las complicaciones (36,67% vs. 3,8%, p < 0,001) como la estancia media hospitalaria en días (10,24[± 5,74] vs. 1,27[± 1,87], p < 0,001) fue mayor en la RQ frente a RE. La resección se logró eficazmente en 91 casos de RE (86,7%) comparable con la RQ que fue de 29 casos (96,7%), p = 0,19; aunque para ello se necesitó mayor número de colonoscopias en los pacientes a los que se les practicó RE (endoscopias en 24 meses de seguimiento post-resección: 0,97[± 0,74] vs. 0,60[± 0,56], p = 0,01).
AB0422 Orofacial evaluation in women with rheumatoid arthritis
Authors: C.P.S. Hoyuela, R.N.V. Furtado, A. Chiari, J. Natour
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Rheumatoid arthritis (RA) can affect any synovial joint. Unlike the hand, ever so valued in the physical examination of patients with RA, the joints in the area of the jaw and neck may also be affected in this disease and have their involvement usually underdiagnosed. There are few studies evaluating the incidence of orofacial alteration in the examination as well as the correlation between bite force (BF) and clinical and functional parameters in these patients. <h3>Objectives</h3> The aim of our study was to compare the orofacial evaluation of women with RA with a control group, correlating orofacial function parameters with clinical disease activity in RA patients and hand strength in RA patients and control subjects. <h3>Methods</h3> We conducted a cross-sectional study with 150 women: half of them (n=75) were RA patients and the others (n=75) consisted the control group. The two groups were paired by age. All individuals we evaluated in relation to: pain duringmandibular function; TMJ pain at rest; TMJ sounds; tiredness during mastication; complaint of changes in the occlusion pattern; vertical range of motion of the mandible; reports chewing fatigue;reports of bruxism; reports of feeling morning stiffness in the TMJ; pain in TMJ lateral pole; BF of three regions: incisors and molars; assess the pinch (key,tip, palmar) and grip strenght; DASH and HAQ questionnaires; DAS 28 and OHIP14 questionnaire (Oral Health Impact Profile). <h3>Results</h3> The mean age (±SD) of the RA group was 49.2 years (±9.4) and 47.4 (±10.0) of the control group (p=0.244). Duration of disease of the RA group was 12.66 years (±9,32). Only 2 (2.6%) patients in the RA group reported TMJ pain at rest and during function; it was observed in RA and control group respectively: sounds in 36 (48.0%), 11 (14.6%); mouth opening in 44.13 mm (± 6.95), 46.48 mm (± 6.09); chewing fatigue in12 (16.0%), 5 (6.6%); pain inlateral pole TMJ in 29 (38.6%), 6 (8%); sleep bruxism in 21 (28.0%), 19 (25.3%); wakefulness bruxism in 13 (17.3%), 13 (17.3%); changes in the occlusion pattern in 7 (9.3%),1 (1.3%). The mean BF values of the RA and control groups in the three regions (incisors, right molars and left molars) were respectively: Incisor 92.8N (± 53.8), 126.5N (± 59.8), p=0.002; right molars 154.7N (± 104.4), 252.7N (± 149.7), p&lt;0.001; 170.3N left molars (± 121.0), 249.2N (± 155.7), p=0.002. p&lt;0.001; In RA group, there was no correlation between the BF and OHIP-14, DASH and DAS-28,was correlation and incisor force and key pinch (r=0.317,p=0.006), palmar pinch (r=0,317,p=0.006), and HAQ (r =- 0,488, p=0.0001);molar force and key pinch (r=0,275,p=0.032) and HAQ (r=-0.256,p=0.045). <h3>Conclusions</h3> We found women with RA have lower BF and more signs and symptoms in the orofacial region when compared to healthy ones. There was correlation between the BF and functional parametersand pinch strength in these patients. <h3>Disclosure of Interest</h3> None Declared
Abstract 1539: Lovastatin sensitizes tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis through inactivation of NF-kB pathway and activation of JNK/p38 pathway in human glioblastoma cells
Authors: Pi-chu Liu, Jun Li, George G. Chen, Gang Lu, Wai S. Poon
Journal: Cancer Research (2010)

Abstract Glioblastoma (GBM) is among the deadliest of all human cancers. Tumor Necrosis Factor-Related Apoptosis Inducing Ligand (TRAIL) becomes a promising candidate for GBM therapy, not only for its strong antitumor activity in a wide range of cancer cell types, but also for its minimal cytotoxity to most normal cells. The main barrier in TRAIL-based therapies, however, is TRAIL resistance (including GBM-derived cell lines and primary cells). Methods overcome TRAIL resistance can largely enhance the effect of TRAIL-based therapy. In this regard, we have reported that lovastatin could sensitize GBM cells to TRAIL, but the underlying mechanism remains largely unknown. Our data suggested that lovastatin could up-regulate DR5 (TRAIL-R2) expression, which might contribute to the sensitization of GBM cells to TRAIL by lovastatin. Here we provide preliminary results suggesting that the mitogen-activated protein kinase (MAPK) signaling (p&amp;lt;0.001) was significantly dysregulated after lovastatin treatment, by microarray pathway analysis in three GBM cell lines (A172, M059J and M059K). Furthermore, we demonstrated that lovastatin sensitized GBM cells to TRAIL by inhibiting ERK/MAPK and activating JNK/p38. In addition, NF-kB was reported to be involved in DR5 regulation. In this study, we further characterized the role of NF-kB signaling in TRAIL resistant GBM cell sensitization by lovastatin and especially its relation to TRAIL receptors. We have extended our study to investigate the mechanism of lovastatin sensitizing GBM cells to TRAIL. We first showed that lovastatin down-regulaetd cRelA/p65, one of the components of NF-κB subunit, which was reported to suppress DR-5 expression. This finding suggested that lovastatin might sensitize GBM cells to TRAIL by cRelA/p65 inactivation. Moreover, we found that the inactivation of cRelA/p65 was through down-regulation of its inhibitory IκB protein degradation and IKKα/ β after lovastatin treatment. In addition, we found that inhibition of NF-κB up-regulated DR5 expression. Findings obtained not only provides new insights into TRAIL resistant death signaling via both intrinsic and extrinsic pathways, but also is essential for developing new target-specific and safe strategy to overcome TRAIL resistance for future clinical application. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 1539.
ED-36 * INHERITED VARIANTS NEAR TERC AND TERT ARE ASSOCIATED WITH LONGER TELOMERES AND INCREASED GLIOMA RISK: GENOME-WIDE ASSOCIATION RESULTS FROM THE UCSF ADULT GLIOMA STUDY AND THE ENGAGE CONSORTIUM TELOMERE GROUP
Authors: K. Walsh, V. Codd, I. Smirnov, T. Rice, P. Decker, H. Hansen, A. Molinaro, M. Pekmezci, T. Tihan, M. Berger, S. Chang, M. Prados, D. Lachance, B. P. O'Neill, P. van der Harst, J. Wiencke, N. Samani, R. Jenkins, M. Wrensch
Journal: Neuro-Oncology (2014)

High-grade glioma, the most common central nervous system cancer in adults, has poor prognosis. We performed a genome-wide association study (GWAS) and replication analysis of high-grade glioma risk (N = 1,644 cases and 7,736 controls). We identify a novel inherited glioma risk locus, rs1920116 (near TERC), that achieved genome-wide statistical significance (Pcombined = 8.3 × 10−9). We also validate a previously identified glioma risk locus, rs2736100, in TERT (Pcombined = 1.4 × 10−15). Because TERC and TERT are subunits of the telomerase enzyme, and variants in both genes have previously been associated with mean leukocyte telomere length (LTL), we examined the relationship between telomere length and glioma risk loci using data from a recent GWAS of LTL (N = 37,684 individuals). The top glioma risk alleles near TERC and TERT were strongly associated with longer telomere length (P = 5.5 × 10−20 and 4.4 × 10−19, respectively). In a ∼100kb haplotype block containing the TERC gene, every SNP which was associated with glioma at P < 0.01 (N = 54 SNPs) was also associated with longer telomeres at P < 1.0x10−5. Associations in TERT were similarly uniform. Glioma risk alleles near RTEL1 were inconsistently associated with telomere length, suggesting the presence of distinct causal alleles at this locus. No other glioma risk loci were associated with telomere length. The identification of alleles that are strongly associated with both increased glioma risk and longer telomeres suggests that heritable variation in telomere length or telomerase activity may underlie glioma susceptibility.
AB0125 A crucial role for lectin-like oxidized LDL receptor-1 signal on synovial inflammation in RA
Authors: H. Ito, M. Ishikawa, M. Akiyoshi, K. Murata, S. Tanida, H. Shibuya, T. Kasahara, H. Yoshitomi, T. Nakamura
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> LOX-1 (Lectin-like oxidized LDL receptor 1), one of functional receptors for oxidized LDL (ox-LDL), is expressed in various cells and its expression is enhanced by oxidative stress and inflammatory cytokines. However, little is known whether LOX-1 is expressed in the RA synovium or synovial cells and whether soluble form of LOX-1 (sLOX-1) has any potential diagnostic roles in human RA. <h3>Objectives</h3> To determine whether LOX-1 and sLOX-1 are novel target molecules for the diagnosis and the treatment of RA. <h3>Methods</h3> Human RA synovium and fibroblast-like synoviocytes (FLSs) were assessed for the expression of LOX-1 and production of MMP-1 and MMP-3 induced by ox-LDL.Levels of sLOX-1 in plasma and in synovial fluid were determined by a specific ELISA.Ox-LDL was injected intoknee joints of mice with or without an anti-LOX-1 neutralizing antibody or sLOX-1. <h3>Results</h3> The ox-LDL and LOX-1 protein were presentin the synovialtissues in RA joints. The production of MMP-1 and MMP-3 were enhanced by the stimulation of FLSs with ox-LDL and were inhibited by blockade of ox-LDL–LOX-1 interaction with an anti-LOX-1 neutralizing antibody or sLOX-1. sLOX-1 levels were significantly higher in the plasma and synovial fluid of RA patients compared withosteoarthritispatients and healthy controls,andwere positively correlated withinflammatory markers and with disease activity of RA. Blockade of ox-LDL–LOX-1 interaction suppressed arthritic changesand MMP-3 expressioninduced by ox-LDLin the knees of mice. <h3>Conclusions</h3> These findings strongly indicate that sLOX-1 is a novel biomarker for the diagnosis and the evaluation of disease activity of RA, and that LOX-1 may be a potent therapeutic target for RA. <h3>Disclosure of Interest</h3> None Declared
OP0148 Effectiveness of Conventional DMARDS Using A Treat to Target Strategy in the Context of A Large Cohort of Rheumatoid Arthritis Patients:
Authors: P. Santos-Moreno, G. Saavedra-Martinez, L. Villarreal, A. Palomino, V. Giraldo, D. Gomez, J. Bello-Gualtero
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> The importance of early effective therapy, implications of disease activity in progression and use of composite disease activity measures in rheumatoid arthritis (RA), led to developing of defined therapeutic targets and tools to achieve them resulting in the Treat to Target (T2T) initiative. This strategy is being used last 2 years in Colombia in a specialized in RA center. <h3>Objectives</h3> The aim of this study was to describe general change in Disease Activity Score 28 (DAS28) using A T2T strategy during a 24 month period in a large cohort of RA patients treated with conventional DMARDs. <h3>Methods</h3> A descriptive cross-sectional study was performed. Patients from a rheumatologic center with diagnosis of RA (ACR 1987 and 2010 ACR/EULAR criteria) were assessed applying a T2T strategy. A standardized follow-up was designed using DAS28: every 3-5 weeks (DAS28 &gt;5.1), every 7-9 weeks (DAS28 ≥3.2 and ≤5.1), and every 11-13 weeks (DAS28 &lt;3.2). In case of DAS28 &gt;3.2 it was mandatory to introduce adjustments in treatment based on a predetermined clinical guideline. We calculated percentages and averages from this data and divided patients in four groups: remission (Rem), low disease activity (LDA), moderate disease activity (MDA) and severe disease activity (SDA). Global change in DAS28 was determined at beginning, 6, 12, and 24 months an assessed using Chi-square test. <h3>Results</h3> 705 patients were included in this study, 560 (79.3%) women and 145 (20.5%) men. All patients had established disease (more than 2 years of duration) and average age 60.1 y/o. Regarding the entire cohort, majority of patients were using DMARDs alone or in combination 450 (63.8)% of patients were using methotrexate, 481 (68.22%) leflunomide, 176 (24.9%) sulfasalazine, and prednisolone 126 (17.8%). The difference of medians for each variable showed improvement with statistical significance (p&lt;0.00). <h3>Conclusions</h3> This study shows general improvement of DAS28 in RA patients treated with conventional DMARDs applying a T2T strategy; it was found a globally increase in the percentage of patients in remission group and decrease in MDA/SDA groups. Standard T2T follow-up in patients with RA should be done based on: correct use of disease activity scores and visits/treatment decisions based on, and was proved that achieving remission/LDA using only conventional DMARDs is a realistic goal in clinical practice. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.4824